High expression of MIF was found to correlate with poor response to ICB therapy in melanoma patients, supporting the potential of combining anti-CTLA-4 with MIF inhibitors as a strategy to enhance ICB therapy response and promote innate immunity activation, metabolic reprogramming, and reduced PD-L1 expression in melanoma cells. Here, MIF is linked to melanoma.